Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib, Pembrolizumab, and Paclitaxel in Recurrent Endometrial and Platinum-Resistant Ovarian Cancers
NCT04781088Phase 2Active, not recruiting
- Start
- Sep 2021
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib, pembrolizumab and Paclitaxel Micelles for Injection in endometrial cancer (EC), ovarian cancer, fallopian tube cancer (PFTC) and 1 more. Primary endpoint: Objective Tumor Response at 1 year. Started Sep 2021; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04781088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781088.